A method of identifying treatment relevant neoepitopes for use in guided immunotherapy of a patient diagnosed with a tumour, comprising: receiving omics data for tumour cells in a first location in the patient, and receiving omics data for tumour cells in a second location in the patient, wherein the first and second locations are different anatomical locations, and wherein the omics data is obtained using nucleic acid sequencing, RNA sequencing, protein sequencing or mass spectroscopy based sequencing; using the omics data to determine respective neoepitopes in the tumour cells of the first and second locations; determining by a computer-implemented method, at least one of a group attribute, a location attribute, a function attribute, a metabolic attribute, and a pathway attribute of each determined respective neoepitope, wherein the group attribute is selected from the group consisting of a unique neoepitope, a shared neoepitope, ploidy status, and clonality status, wherein the location attribute is selected from the group consisting of primary tumour location, a metastasis location, and a circulatory system, wherein the function attribute is selected from the group consisting of a driver mutation, a passenger mutation, and methylation status, wherein the metabolic attribute is selected from the group consisting of drug resistance and increased glycolysis, and wherein the pathway attribute is selected from the group consisting of a mutation in a growth signaling pathway, a mutation in an apoptosis signaling pathway, a mutation in a hormonal signaling pathway, and a shift in signaling pathway usage; filtering the respective neoepitopes against an HLA-type of the patient, comprising: determining the HLA-type of the patient; calculating binding affinities of the respective neoepitopes to the determined HLA-type of the patient; selecting high-affinity neoepitopes for the first and second locations that have a binding affinity to the determined HLA-type of the patient of less than 500 nM; and selecting, from among the high-affinity neoepitopes in the tumour cells of the first and second locations, treatment relevant neoepitopes sharing at least one of a group attribute, a location attribute, a function attribute, a metabolic attribute, and a pathway attribute. receiving omics data for tumour cells in a first location in the patient, and receiving omics data for tumour cells in a second location in the patient, wherein the first and second locations are different anatomical locations, and wherein the omics data is obtained using nucleic acid sequencing, RNA sequencing, protein sequencing or mass spectroscopy based sequencing; using the omics data to determine respective neoepitopes in the tumour cells of the first and second locations; determining by a computer-implemented method, at least one of a group attribute, a location attribute, a function attribute, a metabolic attribute, and a pathway attribute of each determined respective neoepitope, wherein the group attribute is selected from the group consisting of a unique neoepitope, a shared neoepitope, ploidy status, and clonality status, wherein the location attribute is selected from the group consisting of primary tumour location, a metastasis location, and a circulatory system, wherein the function attribute is selected from the group consisting of a driver mutation, a passenger mutation, and methylation status, wherein the metabolic attribute is selected from the group consisting of drug resistance and increased glycolysis, and wherein the pathway attribute is selected from the group consisting of a mutation in a growth signaling pathway, a mutation in an apoptosis signaling pathway, a mutation in a hormonal signaling pathway, and a shift in signaling pathway usage; filtering the respective neoepitopes against an HLA-type of the patient, comprising: determining the HLA-type of the patient; calculating binding affinities of the respective neoepitopes to the determined HLA-type of the patient; selecting high-affinity neoepitopes for the first and second locations that have a binding affinity to the determined HLA-type of the patient of less than 500 nM; and determining the HLA-type of the patient; calculating binding affinities of the respective neoepitopes to the determined HLA-type of the patient; selecting high-affinity neoepitopes for the first and second locations that have a binding affinity to the determined HLA-type of the patient of less than 500 nM; and selecting, from among the high-affinity neoepitopes in the tumour cells of the first and second locations, treatment relevant neoepitopes sharing at least one of a group attribute, a location attribute, a function attribute, a metabolic attribute, and a pathway attribute.